Table 2. Comparison of demographic characteristics and features of therapy between patients treated with and without prophylactic antiemetics for acute and delayed CINV (N=14,548).
| Characteristics | Acute CINV | Delayed CINV | |||||
| No antiemetic prophylaxis (N=1,463) (%) |
Prophylactic antiemetics (N=13,085) (%) |
P value | No antiemetic prophylaxis (N=4,145) (%) |
Prophylactic antiemetics (N=10,403) (%) |
P value | ||
| Demographics | |||||||
| Age, yearsa | 0.075 | 0.010 | |||||
| <30 | 28 (1.9) | 241 (1.8) | 80 (1.9) | 189 (1.8) | |||
| 30–39 | 86 (5.9) | 814 (6.2) | 281 (6.8) | 619 (6.0) | |||
| 40–49 | 251 (17.2) | 2,582 (19.8) | 820 (19.8) | 2,013 (19.4) | |||
| 50–59 | 480 (32.8) | 4,264 (32.6) | 1,372 (33.2) | 3,372 (32.5) | |||
| 60–69 | 385 (26.3) | 3,410 (26.1) | 1,011 (24.4) | 2,784 (26.7) | |||
| 70–79 | 215 (14.7) | 1,638 (12.5) | 526 (12.7) | 1,327 (12.8) | |||
| ≥80 | 18 (1.2) | 115 (0.9) | 51 (1.2) | 82 (0.8) | |||
| Gender | 0.001 | <0.001 | |||||
| Male | 748 (51.1) | 6,111 (46.7) | 1,859 (44.8) | 5,000 (48.1) | |||
| Female | 715 (48.9) | 6,974 (53.3) | 2,286 (55.2) | 5,403 (51.9) | |||
| Type of hospital | <0.001 | 0.022 | |||||
| Cancer center | 392 (26.8) | 2,446 (18.7) | 858 (20.7) | 1,980 (19.0) | |||
| General hospital | 1,071 (73.2) | 10,639 (81.3) | 3,287 (79.3) | 8,423 (81.0) | |||
| Grade of hospitala | 0.029 | 0.280 | |||||
| Grade 3 | 1,254 (86.2) | 11,049 (85.1) | 3,523 (85.5) | 8,780 (85.1) | |||
| Grade 2 | 185 (12.7) | 1,671 (12.9) | 528 (12.8) | 1,328 (12.8) | |||
| Grade 1 or below | 15 (1.1) | 265 (2.0) | 68 (1.7) | 212 (2.1) | |||
| Type of antiemetic therapyb | |||||||
| Single drug | 827 (6.3) | 762 (7.3) | |||||
| Multiple drugs | 12,210 (93.3) | 9,600 (92.3) | |||||
| H/A only | 48 (0.4) | 41 (0.4) | |||||
Data are presented as n (%), and differences were tested using the chi-square test. Abbreviations: CINV, chemotherapy-induced nausea and vomiting; H/A, herbal or alternative antiemetic. a, data for age were missing for 21 patients and for grade of hospital for 109 patients. b, data for 14,395 patients were included.